2026-09-21T10:33:28-07:00 2025-12-31 521185156 Lydon Fetterolf Corydon PA 9401 Key West Avenue Rockville MD 20850 990 2025-01-01 061416238 Heart Failure Society of America Inc HEAR 3013128635 500 N Washington St 10009 ROCKVILLE MD 20849 John Barnes CEO 2026-09-21 true Jeff Corydon IV CPA CFP P00297218 3019484400 2025 John Barnes 500 N Washington St 10009 ROCKVILLE MD 20849 11332537 false X HFSA.ORG X 1995 CT Provide a platform to improve and expand heart failure care through collaboration, education, innovation, research and advocacy. 11 11 20 153 11425 1341101 609865 2176661 6840069 302075 747407 334040 1262415 4153877 9459756 254190 0 3206208 3313274 0 202628 3519251 4420567 6725459 7988031 -2571582 1471725 10733696 9825009 4665158 1983732 6068538 7841277 X Provide a platform to improve and expand heart failure care through collaboration, education, innovation, research and advocacy. false false 2964117 4347532 Annual Scientific Meeting (ASM):The HFSA Annual Scientific Meeting (ASM) is the Societys flagship educational and scientific conference, bringing together the multidisciplinary heart failure community to share research, advance clinical knowledge, and discuss emerging therapies and innovations in heart failure care. Following the cancellation of ASM 2024 due to Hurricane Helene, HFSA successfully convened the 2025 Annual Scientific Meeting in Minneapolis, Minnesota, providing an important forum for education, collaboration, and scientific exchange. The meeting featured a comprehensive program spanning basic, translational, and clinical science; advanced heart failure and transplantation; mechanical circulatory support; prevention; health equity; and emerging technologies. In 2025, ASM featured 56 educational sessions, three plenary presentations, more than 500 scientific abstracts, and 7 moderated eposter and oral abstract presentation sessions. The meeting attracted 2,494 attendees, including physicians, advanced practice providers, nurses, pharmacists, researchers, trainees, and other healthcare professionals from across the United States and internationally. 1507476 684307 Education and ProgramsPrograms aimed at education for the entire heart failure team, including cardiologists, nurses, pharmacists, physician assistants, etc. The 2025 initiatives include the Heart Failure Seminars, Contemporary Issues in Heart Failure, CardioHub, and Heart Failure Certification (HF-Cert) Bootcamp. 1) Heart Failure Seminars In 2025, the series addressed important clinical and practice-based topics, including Heart Failure Devices, Cardio-Oncology, Palliative Care in Advanced Heart Failure, Pulmonary Hypertension and Right Ventricular Failure, and Assessment of Heart Failure Patients for Advanced Therapies. Several programs were developed in conjunction with HFSA Scientific Statements, helping translate HFSA guidance into practical clinical education.The series serves a broad spectrum of the heart failure care team, including physicians, nurse practitioners, physician assistants, pharmacists, registered nurses, trainees, and other healthcare professionals. Through expert-led education on diverse areas of heart failure management, the seminar series supports continuing professional education and multidisciplinary collaboration in the care of patients with heart failure. In 2025, the series included five educational programs and engaged 794 live registrants. In addition, 645 healthcare professionals purchased OnDemand access to seminar content, extending the availability of these educational resources beyond the live events. 2) Contemporary Issues in Heart Failure Designed to complement the 2024 HFSA AHFTC Board Certification Review OnDemand program, HFSA launched the Contemporary Issues in Heart Failure OnDemand educational bundle in 2025. This educational offering provides additional learning opportunities for healthcare professionals caring for patients with advanced heart failure and transplantation. While the Board Certification Review Course focuses on foundational knowledge relevant to board examination preparation, Contemporary Issues in Heart Failure addresses clinical topics and challenges encountered in practice. The bundle includes 11 expert-led presentations, each approximately 30 minutes in length, covering emerging therapies, evolving treatment approaches, and complex clinical decision-making in advanced heart failure and transplantation. The program serves physicians, advanced practice providers, pharmacists, nurses, trainees, and other healthcare professionals involved in the care of patients with heart failure. In its first year, launched mid-year, 19 healthcare professionals purchased access to the educational bundle. Through evidence-based educational content, the program supports continuing professional education and provides additional resources to enhance understanding of contemporary issues in advanced heart failure and transplantation. 3) CardioHub HFSA continued and expanded the CardioBites program, rebranding as CardioHub as to encompass multiple types of products. CardioBites is a micro-learning program that is targeted to the busy heart failure care team to provide information on one topic in a three-minute video. Two series initially launched in 2024 were completed in 2025. The Congestion series had three modules and an infographic released in 2025. The Inflammation series also had three modules released in 2025. A new CardioBites series was launched in 2025. CardioBites: HCM is a four-part module series. 2025 also launched three new CardioHub products: CardioBites+, CardioAbstracts, and Cardio Town Halls. CardioBites+ are like the original microlearning CardioBite product but produce longer videos (8-10 minutes rather than 3 minutes) with a single moderator interacting with different faculty over the module series. The CardioBites+ Amyloidosis series released three modules and an infographic. CardioAbstracts are live 45-minute webinar events, featuring video summations of select abstracts which are followed by expert-led discussions on recently presented clinical trial data in a convenient, interactive format, extending the reach of key clinical trial findings. Two CardioAbstract events were held in 2025, on the topics of New ATTR-CM Data, and HF + Kidney Link. Cardio Town Halls are also a 30-minute live seminar which features Q&A with leading clinicians. The events are recorded, and the videos and downloadable resources are available for OnDemand learning. The Cardio Town Hall: Amyloidosis series consisted of four live events, three of which were launched in 2025. 4) HF-Cert Bootcamp HFSA continued sales of its three 90-minute HF-Cert Bootcamp webinars. These three seminars offered a comprehensive study tool for the HF-Cert examination. 5) 2025 Accredited Educational Impact In 2025, HFSA delivered 35 accredited educational activities13 live courses, 19 enduring materials, and 3 manuscript reviewsengaging a total of 2,680 participants across the heart failure care team. These programs provide accessible, high-quality learning opportunities designed to enhance skills, foster collaboration, and ultimately improve patient outcomes. Education Partner Programs Given the cancellation of the 2024 Annual Meeting, HFSA pivoted to delivering high-quality continuing education by transitioning approved satellite programming to virtual and on-demand formats. This approach ensured that healthcare professionals continued to have access to timely, evidence-based education despite the unforeseen circumstances. The virtual educational portfolio addressed many of the most pressing topics in contemporary heart failure care, including advances in heart failure prevention and management, integration of SGLT2 inhibitors across the spectrum of heart failure, recognition and treatment of transthyretin cardiac amyloidosis, innovations in hypertrophic cardiomyopathy management through cardiac myosin inhibition, and the role of intravenous iron therapy for patients with iron deficiency and heart failure. Learner engagement demonstrated the continued demand for accessible, expert-led education. 828258 621416 The Journal of Cardiac Failure (JCF)The Journal of Cardiac Failure (JCF) Family of Journals is the preeminent source for high-quality, innovative science in the field of heart failure and its intersections with diverse disciplines and specialties within the cardiovascular community. As the official journals of the Heart Failure Society of America (HFSA), both JCF and JCF-Intersections are dedicated to advancing knowledge, promoting collaboration, and fostering inclusivity.In 2025, the main JCF Journal published 331 articles, which were 15% of market share based on over 1800 submissions. The Impact Factor for the journal reached 8.2, placing it 19th out of 230 cardiology journals listed. In addition, the journal reached over 1.1 million downloads of articles.JCF-Intersections, the JCF daughter journal, was fully launched in 2025, with appointments of an Editor-in-Chief and full editorial board. The journal published two issues and had 277 submissions.In addition to the 12 monthly issues published, JCF published three HFSA Scientific Statements, along with the updated HF Stats document. The journal also launched its 4th iteration of the JCF Peer Reviewer Mentorship Program. All previous issues and papers published by JCF can be found at www.onlinejcf.com and at https://www.onlinejcfi.org/ 395075 Science and Research ProgramsHFSA's Science and Research programs advance the generation, dissemination, and application of evidence to improve the prevention, diagnosis, treatment, and outcomes of patients living with heart failure. Through scientific statements, research initiatives, national data resources, and collaborative research networks, HFSA supports healthcare professionals, researchers, policymakers, and healthcare organizations by providing evidence-based guidance, fostering scientific collaboration, and promoting innovation in heart failure care. 325735 254190 Heart Failure Research Network (HFRN)The Heart Failure Research Network (HFRN) is HFSA's national collaborative research initiative that connects academic medical centers, health systems, community practices, and clinical investigators engaged in heart failure research. In 2025, HFRN provided opportunities for collaboration, information exchange, and professional engagement through networking activities, educational programming, and discussions focused on advancing heart failure clinical research and improving the clinical trial ecosystem. By fostering collaboration among investigators and research sites, HFRN supports the development and evaluation of therapies designed to improve outcomes for patients living with heart failure. 292507 Governance 50983 Practice and Patient Programs1)Optimal Medical Therapy in Heart failure Certificate Program (OMT-HF)The Optimal Medical Therapy in Heart Failure Certificate Program (OMT-HF) directly supports HFSAs mission to improve heart failure care by equipping non-specialist healthcare providers with the knowledge and tools needed to confidently prescribe and optimize guideline-directed medical therapy (GDMT). Developed to address critical gaps in the implementation of GDMT, the program delivers a structured, evidence-based curriculum that translates complex guidelines into practical clinical decision-making.A total of 423 learners participated in the program during the reporting period, representing a multidisciplinary audience that included 180 nurses, 71 physicians, 55 pharmacists, 25 physician assistants, and 93 additional healthcare professionals. Learner engagement remained strong, with 196 participants completing the program with 194 of those learners claiming continuing education credits.Additionally, a Cleveland Clinic pre- and post-survey analysis demonstrated that program completion significantly improved prescriber comfort with outpatient guideline-directed medical therapy (GDMT) prescribing, dosing, monitoring, and side-effect management across all medication classes, with findings published in the Journal of Cardiac Failure (JCF).Through its multidisciplinary reach and focus on evidence-based clinical education, the OMT Certification Program continues to improve healthcare provider competency and promote more consistent, high-quality heart failure care nationwide.2) Heart Failure Patient & Caregiver Webinar SeriesHFSA Patient & Caregiver Webinar Series, enables a broader reach to more patients and caregivers across the country. In 2025, the series consisted of four webinars, each drawing between 150200 registrants.The goal of the Patient & Caregiver Webinar Series is to provide easy-to-understand, engaging education on all aspects of heart failure, empower patients and caregivers to actively engage in conversations about treatment and management with their healthcare providers, and encourage the use of available resources. The following webinars were held in 2025 as part of the HFSA Heart Failure Patient and Caregiver Series and collectively garnered a total of 596 registrations:Heart Failure Basics: An overview of HF, including causes, symptoms, diagnosis, and initial treatment options.Heart Failure & Obesity: Insights into the relationship between HF and obesity, discussing the impact of weight management on heart health and overall prognosis.Understanding and Managing ATTR Amyloidosis: A foundational overview of ATTR Amyloidosis, including the differences between hereditary and wild-type forms.Heart Failure Devices and Monitoring: Information on various medical devices used in HF treatment and how continuous monitoring can help in managing the condition effectively.The HFSA Heart Failure Patient & Caregiver Webinar Series educational sessions are archived on the HFSA website and YouTube, where patients, caregivers, and family members can access them on demand at no cost. This expanded, on-demand availability has significantly increased the programs reach, resulting in over 5,300 views to date. By making these resources free of charge, HFSA continues to empower and educate a broader audience beyond the live events. Scientific StatementsIn 2025, HFSA published two scientific statements to advance evidence-based care in heart failure:The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive CardiologyThe use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)These statements and supplemental publications provided actionable clinical guidance, supported healthcare provider education, and were cited in national policy discussions to promote high-quality, standardized care. HF StatsHF Stats is HFSA's national heart failure data initiative, developed to provide reliable and accessible statistics on the prevalence, burden, outcomes, treatment, and economic impact of heart failure in the United States. In 2025, HFSA published the annual HF Stats Report in the Journal of Cardiac Failure and continued to maintain HFStats.org, an online resource offering searchable data, reports, figures, fact sheets, and educational materials. These resources support clinicians, researchers, policymakers, advocates, and the public by improving access to evidence-based information and advancing efforts to improve heart failure prevention, treatment, and outcomes. Devices Meeting The Device Task Force organized a single day event, Devices in Heart Failure Meeting: From Mechanisms to Implementation, held immediately before the 2025 ASM. The meeting featured six didactic lecture sessions, two Hands On sessions, and two industry-focused competitive sessions geared towards device companies running trials in early stages. It also included an exhibit hall with 43 exhibitors and included vendor demonstrations from attending industry. 334 attendees purchased the Device Meeting add-on in addition to the ASM, and 84 registrants purchased Device Meeting access only. 1064300 254190 6364151 true true false false false false false false false false true false false false true true true false false false false false false false false false false true false true false false false false false false false false false false false false false false false false false true 51 0 true 20 true true true false false false false false false 0 false false false false false false false false false false X 11 11 false false false false true true false true true false false true true true true true true true true false CT MD X X JOORI JEON 3013128635 500 N Washington St 10009 ROCKVILLE MD 20849 John Barnes CEO 40.00 0.00 X 472862 0 57067 Joori Jeon COO 40.00 0.00 X 306232 0 41213 Kristine Fridgen VP-Meetings and Education 40.00 0.00 204308 0 23903 Michelle Poinelli Director of Dev't 40.00 0.00 135482 0 41933 Deborah Zeldow Dir.-Scie/Research 40.00 0.00 164480 0 10447 Kelly Ventura Dir. of Membership 40.00 0.00 158909 0 10097 Dawn Brennaman Dir.-Patient Prog 40.00 0.00 152367 0 9688 Shauna Brown Director of Educ. 40.00 0.00 117348 0 40261 Michael Givertz President Elect 1.20 0.00 X X 0 0 0 Anekwe Onwuanyi Director 1.20 0.00 X 0 0 0 Martha Abshire Saylor Director 1.20 0.00 X 0 0 0 Mitch Psotka Director 1.20 0.00 X 0 0 0 Colleen McLlvennan Secretary 1.20 0.00 X X 0 0 0 Ken Margulies President 1.20 0.00 X X 0 0 0 Natalie Pierson Director 1.20 0.00 X 0 0 0 Nancy Sweitzer Treasurer 1.20 0.00 X X 0 0 0 Orly Vardeny Director 1.20 0.00 X 0 0 0 Kavita Sharma Director 1.20 0.00 X 0 0 0 Michael Felker Past President 1.20 0.00 X X 0 0 0 1711988 234609 8 false true false Freeman PO Box 734596 Dallas TX 75373 ASM Exhibits/Auto Visual 1076983 The Bridger Group PO Box 630901 Littleton CO 80163 Professional Services 132800 Maritz Global Events -AT&L Inc 1375 North Highway Drive Fenton MO 63099 ASM Regist. Contractor 125540 RSM US LLP 5155 Paysphere Circle Chicago IL 60674 Accounting 127884 Margaret A Clark Writer LLC 7133 Highcrest Ridge Drive Chesterfield VA 23838 Publishing 198725 8 609865 609865 Annual Meeting 541900 4347532 4347532 Education and Programs 541900 74442 74442 Member Dues 541900 1796679 1796679 Publications 541900 621416 609991 11425 6840069 270523 270523 0 0 0 2348716 949 1871425 1356 477291 -407 476884 -407 477291 0 0 0 Insurance Settlement 900099 950000 950000 Other Income 900099 312415 312415 1262415 9459756 8090652 11425 747814 X 254190 254190 0 0 0 1105583 960282 117330 27971 0 1802011 1133772 536482 131757 92492 57190 27889 7413 130828 82273 38440 10115 182360 129475 41943 10942 0 41683 41683 182279 182279 0 0 24993 24993 1057466 875106 182360 0 13456 764 12692 80788 1076 79712 0 28524 28524 578696 524726 46725 7245 0 1817392 1806956 4171 6265 0 0 17320 17320 12743 12743 Journal and Publications 268193 268193 Miscellaneous 147125 129940 16300 885 Bank fees 76894 55184 21710 Taxes and licenses 30050 30000 50 42965 13341 29589 35 7988031 6364151 1421252 202628 1358365 516630 766359 1481392 137875 37875 533836 243786 0 0 0 0 142686 108793 212284 187750 31241 24534 7730931 7339304 0 0 0 32403 72695 10733696 9825009 952912 1023322 1121371 850779 2590875 109631 4665158 1983732 X 5818154 7816277 250384 25000 6068538 7841277 10733696 9825009 1471725 301014 X false true X true false X 1622958 2249179 2275892 2991078 2406544 11545651 3849322 4970143 4534698 467934 5031965 18854062 0 0 0 5472280 7219322 6810590 3459012 7438509 30399713 0 88934 51265 140199 88934 51265 140199 30259514 134318 154157 257589 267086 270523 1083673 22600 58750 11425 92775 134318 154157 280189 325836 281948 1176448 0 148267 286536 1262415 1697218 5606598 7373479 7239046 4071384 8982872 33273379 0.90940 0.92410 0.03540 0.03530 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 41329 20886 20443 170955 166864 4091 24534 457 Plan Liability 72695 Annual Meeting Refunds Payable 36936 109631 X 9735777 301014 301014 9434763 24993 24993 9459756 7963038 7963038 24993 24993 7988031 Part X : FIN48 Footnote The Society follows the accounting standard on accounting for uncertainty in income taxes, which addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under this guidance, the Society may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The guidance on accounting for uncertainty in income taxes also addresses de-recognition, classification, interest and penalties on income taxes, and accounting in interim periods.Management evaluated the Society's tax positions and concluded that the Society had taken no uncertain tax positions that require adjustment to the financial statements to comply with the provisions of this guidance. Currently, the tax years open and subject to examination by the Internal Revenue Service are 2022, 2023, and 2024 tax years. true Brigham and Womens Hospital 75 Francis St Boston MA 02115 042312909 501(C)(3) 75000 0 FMV Research Cleveland Clinic Foundation 6801 Brecksville RD RK1-85 Independence OH 44131 340714585 501(c)(3) 30000 0 FMV Research Medstar Health Res Institute 10980 Grantchester Way Columbia MD 21044 526056274 501(c)(3) 74190 0 FMV Research University of Utah 201 S Presidents Circle Salt Lake City UT 84112 876000525 501(C)(3) 75000 0 FMV Research 0 4 Grantmaker's Description of How Grants are Used grant funds are awarded based on a formal application process with eligibility guidelines. the grant award specifies limitations of use. grantees receiving more than $40,000 are required to submit a six month and final financial report, detailing expenditures. these reports are reviewed for appropriateness. any funds not spent in accordance with grant guidelines are returned to the grantor X X X false false false false false false false true false Dawn Brennaman Dir.-Patient Prog 151667 700 9142 546 162055 Deborah Zeldow Dir.-Scie/Research 163780 700 9869 578 174927 John Barnes CEO 442140 30722 23500 33567 529929 Joori Jeon COO 305532 700 18698 22515 347445 Kelly Ventura Dir. of Membership 158209 700 9534 563 169006 Kristine Fridgen VP-Meetings and Education 203608 700 12271 11632 228211 Michelle Poinelli Director of Dev't 134782 700 8724 33209 177415 Shauna Brown Director of Educ. 116648 700 7028 33233 157609 Part I, Line 7: Non-Fixed payments not listed above The salaried officers of the Organization can earn an annual performance bonus based on predetermined metrics established by the board of directors. Form 990, Part VI, Section A, Line 6 members consist of professionals connected with the field of cardiovascular disease or failure. Form 990, Part VI, Section B, Line 11b the CEO and coo reviews the 990 and distributes copies to the audit committee for approval prior to filing. Form 990, Part VI, Section B, Line 12c all council members disclose potential conflicts on an annual basis. this information is reviewed and monitored by the cme director. Form 990, Part VI, Section B, Line 15a the process for determining the compensation of the ceo involves review and approval by the executive committee, comparability data (guidestar compensation and benefits study), and contemporaneous substantiation of the approval via amendment of the employment agreement. the performance bonus is determined based on evaluations from the leaders of the society that interact with the ceo. Form 990, Part VI, Section B, Line 15b Other officer salaries are established by the ceo and president, and are commensurate with market value and experience. Form 990, Part VI, Section C, Line 19 copies of the Form 990, and other documents are made available upon request. Audited financials and the form 990 are also available on the HFSA website.